Consolidated Statement of Stockholders' Equity (Deficit) (Unaudited) 2 - USD ($)	Clyra Medical Technologies [Member] Common Stock [Member]	Clyra Medical Technologies [Member] Additional Paid-in Capital [Member]	Clyra Medical Technologies [Member] Retained Earnings [Member]	Clyra Medical Technologies [Member] AOCI Attributable to Parent [Member]	Clyra Medical Technologies [Member] Noncontrolling Interest [Member]	Clyra Medical Technologies [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2021							255,893,726
Balance at Dec. 31, 2021							$ 171,000	$ 143,718,000	$ (139,121,000)	$ (115,000)	$ (3,720,000)	$ 933,000
Sale of stock for cash (in shares)							6,703,789
Sale of stock for cash							$ 4,000	1,198,000	0	0	0	1,202,000
Issuance of common stock for services (in shares)							86,752
Issuance of common stock for services							$ 0	17,000	0	0	0	17,000
Stock option compensation expense							0	660,000	0	0	0	660,000
Clyra Medical Technologies, Inc. (Clyra) stock options issued for services	$ 0	$ 141,000	$ 0	$ 0	$ 0	$ 141,000
Noncontrolling interest allocation							0	(528,000)	0	0	528,000	0
Net loss							0	0	(1,652,000)	0	108,000	(1,544,000)
Foreign currency translation							$ 0	0	0	(8,000)	0	(8,000)
Balance (in shares) at Mar. 31, 2022							262,684,267
Balance at Mar. 31, 2022							$ 175,000	145,206,000	(140,773,000)	(123,000)	(3,084,000)	1,401,000
Balance (in shares) at Dec. 31, 2021							255,893,726
Balance at Dec. 31, 2021							$ 171,000	143,718,000	(139,121,000)	(115,000)	(3,720,000)	933,000
Net loss												(3,724,000)
Foreign currency translation												(70,000)
Balance (in shares) at Sep. 30, 2022							274,622,640
Balance at Sep. 30, 2022							$ 184,000	147,470,000	(142,505,000)	(185,000)	(2,931,000)	2,033,000
Balance (in shares) at Mar. 31, 2022							262,684,267
Balance at Mar. 31, 2022							$ 175,000	145,206,000	(140,773,000)	(123,000)	(3,084,000)	1,401,000
Sale of stock for cash (in shares)							5,011,570
Sale of stock for cash							$ 4,000	944,000	0	0	0	948,000
Issuance of common stock for services (in shares)							340,891
Issuance of common stock for services							$ 0	59,000	0	0	0	59,000
Stock option compensation expense							0	234,000	0	0	0	234,000
Clyra Medical Technologies, Inc. (Clyra) stock options issued for services	0	82,000	0	0	0	82,000
Noncontrolling interest allocation							0	(103,000)	0	0	103,000	0
Net loss							0	0	(1,228,000)	0	(105,000)	(1,333,000)
Foreign currency translation							$ 0	0	0	(3,000)	0	(3,000)
Balance (in shares) at Jun. 30, 2022							268,036,728
Balance at Jun. 30, 2022							$ 179,000	146,422,000	(142,001,000)	(126,000)	(3,086,000)	1,388,000
Sale of stock for cash (in shares)							6,207,084
Sale of stock for cash							$ 4,000	1,113,000	0	0	0	1,117,000
Issuance of common stock for services (in shares)							378,828
Issuance of common stock for services							$ 1,000	95,000	0	0	0	96,000
Stock option compensation expense							0	253,000	0	0	0	253,000
Clyra Medical Technologies, Inc. (Clyra) stock options issued for services	0	85,000	0	0	0	85,000
Noncontrolling interest allocation							0	(498,000)	0	0	498,000	0
Net loss							0	0	(504,000)	0	(343,000)	(847,000)
Foreign currency translation							$ 0	0	0	(59,000)	0	(59,000)
Balance (in shares) at Sep. 30, 2022							274,622,640
Balance at Sep. 30, 2022							$ 184,000	147,470,000	(142,505,000)	(185,000)	(2,931,000)	2,033,000
Balance (in shares) at Dec. 31, 2022							278,462,706
Balance at Dec. 31, 2022							$ 186,000	148,435,000	(143,594,000)	(149,000)	(2,867,000)	2,011,000
Sale of stock for cash (in shares)							4,201,402
Sale of stock for cash							$ 3,000	797,000	0	0	0	800,000
Issuance of common stock for services (in shares)							930,490
Issuance of common stock for services							$ 1,000	206,000	0	0	0	207,000
Stock option compensation expense							0	195,000	0	0	0	195,000
Clyra Medical Technologies, Inc. (Clyra) stock options issued for services	0	61,000	0	0	0	61,000
Noncontrolling interest allocation							0	467,000	0	0	(467,000)	0
Net loss							0	0	(247,000)	0	(247,000)	(494,000)
Foreign currency translation							$ 0	0	0	(6,000)	0	(6,000)
Balance (in shares) at Mar. 31, 2023							284,122,581
Balance at Mar. 31, 2023							$ 190,000	150,191,000	(143,841,000)	(155,000)	(2,833,000)	3,552,000
Balance (in shares) at Dec. 31, 2022							278,462,706
Balance at Dec. 31, 2022							$ 186,000	148,435,000	(143,594,000)	(149,000)	(2,867,000)	2,011,000
Net loss												(3,628,000)
Foreign currency translation												(12,000)
Balance (in shares) at Sep. 30, 2023							288,626,570
Balance at Sep. 30, 2023							$ 193,000	153,406,000	(146,369,000)	(161,000)	(3,252,000)	3,817,000
Balance (in shares) at Mar. 31, 2023							284,122,581
Balance at Mar. 31, 2023							$ 190,000	150,191,000	(143,841,000)	(155,000)	(2,833,000)	3,552,000
Sale of stock for cash (in shares)							2,677,169
Sale of stock for cash							$ 2,000	492,000	0	0	0	494,000
Issuance of common stock for services (in shares)							420,911
Issuance of common stock for services							$ 0	75,000	0	0	0	75,000
Stock option compensation expense							0	222,000	0	0	0	222,000
Clyra Medical Technologies, Inc. (Clyra) stock options issued for services	0	66,000	0	0	0	66,000
Noncontrolling interest allocation							0	1,461,000	0	0	(1,461,000)	0
Net loss							0	0	(1,328,000)	0	(298,000)	(1,626,000)
Foreign currency translation							$ 0	0	0	(7,000)	0	(7,000)
Balance (in shares) at Jun. 30, 2023							287,220,661
Balance at Jun. 30, 2023							$ 192,000	152,507,000	(145,169,000)	(162,000)	(3,245,000)	4,123,000
Sale of stock for cash (in shares)							1,190,223
Sale of stock for cash							$ 1,000	202,000	0	0	0	203,000
Issuance of common stock for services (in shares)							215,686
Issuance of common stock for services							$ 0	37,000	0	0	0	37,000
Stock option compensation expense							0	680,000	0	0	0	680,000
Clyra Medical Technologies, Inc. (Clyra) stock options issued for services	$ 0	$ 45,000	$ 0	$ 0	$ 0	$ 45,000
Noncontrolling interest allocation							0	(68,000)	0	0	68,000	0
Net loss							0	0	(1,200,000)	0	(308,000)	(1,508,000)
Foreign currency translation							$ 0	0	0	1,000	0	1,000
Balance (in shares) at Sep. 30, 2023							288,626,570
Balance at Sep. 30, 2023							$ 193,000	$ 153,406,000	$ (146,369,000)	$ (161,000)	$ (3,252,000)	$ 3,817,000